Pharma C Investments - Receipt of Requisition Notice
23/08/2023 14:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230823:nRSW2462Ka&default-theme=true
RNS Number : 2462K Pharma C Investments PLC 23 August 2023
23 August 2023
Receipt of Requisition Notice
Pharma C Investments Plc ("Pharma C" or the "Company") announces that on 21
August 2023 it received a written request from one of its shareholders seeking
to requisition a General Meeting ("GM") of the Company under section 303 of
the Companies Act 2006 (the "Act"). The Directors are currently reviewing
the validity of this requisition request with its lawyers and further
announcements will be made by the Company in due course following this review.
If the requisition has been validly made in accordance with the Act, a further
announcement will be made by the Company relating to the calling of a general
meeting and a notice of GM and accompanying circular will posted to
shareholders.
This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.
The Directors of Pharma C accept responsibility for this announcement.
END
For additional information please contact:
Pharma C Investments
Gavin Sathianathan, Investment Strategy Director
gavin@pharmacinvestments.com
Novum Securities (AQSE Corporate Adviser)
Tel: +44 207 399 9400
David Coffman
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NEXEADPDAFSDEFA